SCHEMBL673609

SCHEMBL673609

Oc1ccc(C#Cc2ccc(O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.74
CA3 P07451 3/20 0.58
CA14 Q9ULX7 3/20 0.58
CA12 O43570 2/20 0.58
CA2 P00918 2/20 0.58
CA9 Q16790 2/20 0.58
CA6 P23280 2/20 0.58
ALOX15 P16050 3/20 0.57
ALDH1A1 P00352 2/20 0.57
CYP3A4 P08684 2/20 0.57
HIF1A Q16665 2/20 0.57
HSD17B10 Q99714 2/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
KDM4E B2RXH2 1/20 0.57
NPC1 O15118 1/20 0.57
GMNN O75496 1/20 0.57
CA1 P00915 1/20 0.57
LMNA P02545 1/20 0.57
MAPT P10636 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14400750 1.00 APP (0.74) APPCA3CA14CA12CA2
SCHEMBL21903464 0.94 APP (0.75) APPCA3CA14CA12CA2
SCHEMBL12711690 0.91 ESR1 (0.65) APPCA3CA14CA12CA2
SCHEMBL14400752 0.91 ESR1 (0.65) APPCA3CA14CA12CA2
SCHEMBL18549484 0.88 APP (0.67) APPCA3CA14CA12CA2
SCHEMBL673158 0.88 APP (0.61) APPCA3CA14CA12CA2
SCHEMBL717647 0.88 APP (0.67) APPCA3CA14CA12CA2
SCHEMBL10411992 0.87 APP (0.59) APPCA3CA14CA12CA2
SCHEMBL7889999 0.86 ACHE (0.68) APPCA3CA14CA12CA2
SCHEMBL15014195 0.86 APP (0.65) APPCA3CA14CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280402-B1 TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING BIOMENDICS LLC (US) 2024-06-05 EP claimed
US-11786481-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2023-10-17 US claimed
US-11351126-B2 Substituted tolans for the modulation of microbial colonization BioMendics, LLC (US) 2022-06-07 US claimed
US-20210228501-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2021-07-29 US claimed
CN-111526873-A Substituted tolanes for regulating microbial colonization 生物曼迪克斯有限责任公司 2020-08-11 CN claimed
US-20200206154-A1 Substituted Tolans for the Modulation of Microbial Colonization BioMendics, LLC (US) 2020-07-02 US claimed
EP-3658128-A1 SUBSTITUTED TOLANS FOR THE MODULATION OF MICROBIAL COLONIZATION Biomendics, LLC (US) 2020-06-03 EP claimed
US-10426742-B2 Formulation and process for modulating wound healing BioMendics, LLC (US) 2019-10-01 US claimed
WO-2019023425-A1 SUBSTITUTED TOLANS FOR THE MODULATION OF MICROBIAL COLONIZATION BioMendics, LLC (US) 2019-01-31 WO claimed
US-20190022029-A1 Formulation and Process for Modulating Wound Healing BioMendics, LLC (US) 2019-01-24 US claimed
US-6599945-B2 Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE 2003-07-29 US claimed
US-6054193-A VERY SHORT RESPONSE TIMES, LARGE OPERATING TEMPERATURE RANGE, HIGH CHARACTERISTIC LINE STEEPNESS, GOOD ANGLE DEPENDENCE OF THE CONTRAST AND LOW THRESHOLD VOLTAGE USING A MIXTURE OF LIQUID CRYSTALS ONE OF WHICH CONTAINS A TOLAN-4,4'-DIYL UNIT MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-04-25 US claimed
EP-0379058-B1 Vinyl ester resins containing mesogenic/rigid rodlike moieties DOW CHEMICAL CO (US) 1999-09-29 EP claimed
US-5702640-A CONTAINING NEMATIC LIQUID CRYSTAL MIXTURE INCLUDING AT LEAST THREE DIPHENYLACETYLENE COMPOUNDS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1997-12-30 US claimed
US-5342904-A Polymer modified adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties THE DOW CHEMICAL COMPANY (US) 1994-08-30 US claimed
US-5235008-A Curable THE DOW CHEMICAL COMPANY (US) 1993-08-10 US claimed
US-5182340-A Molding materials having shorter gel time with aliphatic amine curing agents THE DOW CHEMICAL COMPANY (US) 1993-01-26 US claimed
US-5164464-A Liquid crystalline polymers, acrylated epoxy resins THE DOW CHEMICAL COMPANY (US) 1992-11-17 US claimed
US-4962163-A ADVANCED POLYEPOXIDES AND EPOXY RESINS MODIFIED BY AN UNSATURATED CARBOXYLIC ACID; CURED COATING AND FILMS HAVINGI IMPROVED TENSILE AND FLEXURAL STRENGTH AND MODULUS THE DOW CHEMICAL COMPANY (US) 1990-10-09 US claimed
EP-0379058-A2 Vinyl ester resins containing mesogenic/rigid rodlike moieties THE DOW CHEMICAL COMPANY (US) 1990-07-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786481-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB APP 4010/4885CA3 4568/4885CA14 4695/4885
US-20200206154-A1 Substituted Tolans for the Modulation of Microbial Colonization LMAN1, DPM1, DSTN APP 3466/4885CA3 4790/4885CA14 4768/4885
US-20210228501-A1 Formulation and Process for Modulating Wound Healing ATG7, SQSTM1, ATF4 APP 3850/4885CA3 4323/4885CA14 4749/4885
US-10426742-B2 Formulation and process for modulating wound healing SQSTM1, ATG7, TFEB APP 4010/4885CA3 4568/4885CA14 4695/4885
US-20190022029-A1 Formulation and Process for Modulating Wound Healing SQSTM1, ATG7, TFEB APP 4010/4885CA3 4568/4885CA14 4695/4885
US-11351126-B2 Substituted tolans for the modulation of microbial colonization LMAN1, DPM1, DSTN APP 3466/4885CA3 4790/4885CA14 4768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.